Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China

CompletedOBSERVATIONAL
Enrollment

1,077

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

September 29, 2018

Study Completion Date

September 29, 2018

Conditions
Breast CancerNeoadjuvant TherapyNeoplasm StagingEstrogen ReceptorHistological GradeHER2PrognosisPredictive Value of Tests
Trial Locations (12)

100034

Peking University First Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100071

Affiliated Hospital of Academy of Military Medical Sciences, Beijing

110001

The First Hospital of China Medical University, Shenyang, Liaoning, China, Shenyang

130021

The First Hospital of Jilin University, Changchun

150086

The Second Affiliated Hospital of Harbin Medical University, Harbin

250033

Second Affiliated Hospital of Shantou University Medical College, Jinan

350001

Affiliated Union Hospital of Fujian Medical University, Fuzhou

450008

Henan Cancer Hospital, Zhengzhou

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

710032

Xijing Hospital, The Fourth Military Medical University, Xi'an

050011

The 4th Hospital of Hebei medical university, Shijiazhuang

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT03437837 - Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China | Biotech Hunter | Biotech Hunter